Consultant Patrick Poulin Inc., Québec City, Québec, Canada; School of Public Health, Université de Montréal, Montréal, Québec, Canada.
DMPK, Development Science, UCB Pharma, Braine I'Alleud, Belgium.
J Pharm Sci. 2024 Jan;113(1):118-130. doi: 10.1016/j.xphs.2023.08.018. Epub 2023 Aug 25.
In-vitro models are available in the literature for predicting the volume of distribution at steady-state (Vd) of drugs. The mechanistic model refers to the tissue composition-based model (TCM), which includes important factors that govern Vd such as drug physiochemistry and physiological data. The recognized TCM published by Rodgers and Rowland (TCM-RR) and a subsequent adjustment made by Simulations Plus Inc. (TCM-SP) have been shown to be generally less accurate with neutral compared to ionized drugs. Therefore, improving these models for neutral drugs becomes necessary. The objective of this study was to propose a new TCM for improving the prediction of Vd for neutral drugs. The new TCM included two modifications of the published models (i) accentuate the effect of the blood-to-plasma ratio (BPR) that should cover permeated molecules across the biomembranes, which is lacking in these models for neutral compounds, and (ii) use a different approach to estimate the binding in tissues. The new TCM was validated with a large dataset of 202 commercial and proprietary compounds including preclinical and clinical data. All scenario datasets were predicted more accurately with the TCM-New, whereas all statistical parameters indicate that the TCM-New showed significant improvements in terms of accuracy over the TCM-RR and TCM-SP. Predictions of Vd were frequently more accurate for the TCM-new with 83% within twofold error versus only 50% for the TCM-RR. And more than 95% of the predictions were within threefold error and patient interindividual differences can be predicted with the TCM-New, greatly exceeding the accuracy of the published models. Overall, the new TCM incorporating BPR significantly improved the Vd predictions in animals and humans for neutral drugs, and, hence, has the potential to better support the drug discovery and facilitate the first-in-human predictions.
文献中提供了用于预测药物稳态分布容积(Vd)的体外模型。该机制模型是指基于组织组成的模型(TCM),其中包括控制 Vd 的重要因素,如药物物理化学性质和生理数据。已证明 Rodgers 和 Rowland(TCM-RR)发表的公认 TCM 和 Simulations Plus Inc.(TCM-SP)进行的后续调整对于与离子化药物相比,中性药物的准确性通常较低。因此,有必要改进这些中性药物的模型。本研究的目的是提出一种新的 TCM,以提高对中性药物 Vd 的预测。新的 TCM 包括对已发表模型的两项修改:(i)强调血-血浆比(BPR)的作用,BPR 应涵盖穿过生物膜的渗透分子,这在这些中性化合物模型中是缺乏的;(ii)使用不同的方法来估计组织中的结合。新的 TCM 使用包括临床前和临床数据在内的 202 种商业和专有化合物的大型数据集进行了验证。所有方案数据集的预测都被 TCM-New 更准确地预测,所有统计参数都表明 TCM-New 在准确性方面明显优于 TCM-RR 和 TCM-SP。对于 TCM-New,Vd 的预测通常更准确,83%的预测在两倍误差内,而 TCM-RR 仅为 50%。超过 95%的预测误差在三倍以内,并且可以使用 TCM-New 预测患者个体间的差异,这大大超过了已发表模型的准确性。总体而言,新的 TCM 结合 BPR 显著提高了中性药物在动物和人体内的 Vd 预测,因此有潜力更好地支持药物发现并促进首次人体预测。